Agentic AI, which is an autonomous AI system designed to make decisions without human supervision, is gaining traction in EHS. In an industrial setting, hundreds of IoT sensors constantly feed data ...

DULUTH — The nice thing about making a "Tron" sequel is that when it comes to dialogue and character development, the bar is not high. Disney knew it wasn't hiring Robert Altman when it greenlit ...

Novo Nordisk has struck a deal to buy Akero Therapeutics for up to $5.2 billion, teeing up a showdown with Roche and others in a blockbuster liver disease market. Akero confirmed its status as a key ...

Novo Nordisk is ending all work in cell therapy, including a Type 1 diabetes program, amid CEO Maziar Mike Doustdar's reorganization. As part of the move, the company is laying off nearly all of the ...

Novo Nordisk is drawing divided views from Wall Street analysts. Some may be disappointed by the loss of market share to Eli Lilly. Three events could turn sentiment positive in the coming months. The ...

Novo Nordisk A/S (NYSE:NVO) is down 1% to trade at $59 this morning, after news surfaced that the pharmaceutical concern has entered an agreement to purchase U.S.-based peer Akero Therapeutics Inc ...

Oct 10 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab has decided to discontinue its cell therapy research and development efforts, a spokesperson for the Danish drugmaker told Reuters on Friday.

Ozempic maker Novo Nordisk (NVO) is closing its cell therapy division as part of a major restructuring drive initiated under the company’s new CEO, Mike Doustdar, Bloomberg News reported on Thursday, ...

Novo Nordisk A/S agreed to buy Akero Therapeutics Inc. for as much as $5.2 billion to expand its portfolio in a type of liver disease that’s linked to obesity. Novo will pay $54 a share in cash, ...